Notice Number: NOT-EB-17-009

Key Dates
Release Date: August 4, 2017

Issued by
National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this notice is to inform applicants that effective August 4, 2017, the National Institute of Biomedical Imaging and Bioengineering (NIBIB), will no longer be participating in PA-16-040, “Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21)s”.

NIBIB will continue to accept R21 applications under separate NIBIB Program Announcements such as:
1. The NIBIB Trailblazer Award for New and Early Stage Investigators (PAR-16-309, https://grants.nih.gov/grants/guide/pa-files/PAR-16-390.html), which is an opportunity for New and Early Stage Investigators to pursue research programs of high interest to the NIBIB (https://www.nibib.nih.gov/research-funding) that integrate engineering and the physical sciences with the life and/or behavioral sciences.  This FOA invites applications from researchers who are at the early stage of their independent careers or those who have not had substantial prior NIH funding (see https://grants.nih.gov/policy/new_investigators/index.htm for the definition of an NIH New and Early Stage Investigator). A Trailblazer project may be exploratory, developmental, proof of concept, and/or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.  Importantly, applicants are expected to propose research approaches for which there are minimal or no preliminary data.

2. The NIBIB Exploratory/Developmental Research Grant Program R21 Award (PAR-17-441,
https://grants.nih.gov/grants/guide/pa-files/PAR-17-441.html) which supports exploratory/developmental research programs of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.

3. R21 applications submitted in response to specific, topical FOAs that the NIBIB is participating on that are not listed above.

We highly encourage applicants to contact an NIBIB Program Officer to determine if your application fits the mission of the NIBIB and its Programs as well as our new funding strategies for R21s.

Projects from Investigators that are supported by preliminary data should be submitted to the Parent R01 FOA (https://grants.nih.gov/grants/guide/pa-files/PA-16-160.html) or the Bioengineering Research Grant FOA (https://grants.nih.gov/grants/guide/pa-files/PAR-16-242.html).

PA-16-040 is modified as follows:

Currently reads:
Components of Participating Organizations
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Cancer Institute (NCI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Modified to read:
Components of Participating Organizations
National Cancer Institute (NCI)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Inquiries

Please direct all inquiries to:

Randy King, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-0707
Email: Randy.King@nih.gov